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Summary 
Zn
2+ ions were found to efficiently inhibit activated protein C (APC), suggesting a potential 
regulatory function for such inhibition. APC activity assays employing a chromogenic 
peptide substrate demonstrated that the inhibition was reversible and the apparent KI was 
132 M. kcat was 7-fold decreased whereas KM was unaffected in the presence of 10 M 
Zn
2+. The inhibitory effect of Zn
2+ on APC activity was also observed when factor Va was 
used as a substrate in an assay coupled to a prothrombinase assay.  The interaction of Zn
2+ 
with APC was accompanied by a reversible 40% decrease in tryptophan fluorescence, 
consistent with the ion inducing a conformational change in the protein. The apparent KD was 
7.41.5 M and thus correlated well with the apparent KI. In the presence of physiological 
Ca
2+ concentration the KI and KD values were 3–4-fold enhanced, presumably due to the 
Ca
2+-induced conformational change affecting the conformation of the Zn
2+-binding site. The 
inhibition mechanism was non-competitive both in the absence and presence of Ca
2+. 
Comparisons of sequences and structures suggested several possible sites for zinc binding. 
The magnitude of the apparent KI in relation to the blood and platelet concentrations of Zn
2+ 
supports a physiological role for this ion in the regulation of anticoagulant activity of APC. 
These findings broaden the understanding of this versatile serine protease and enable the 
future development of potentially more efficient anticoagulant APC variants for treatments of 
thrombotic diseases. 
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Introduction 
 
Activated protein C (APC) is a 60 kDa blood plasma glycoprotein, which functions as an 
important vitamin K-dependent serine protease down-regulating blood coagulation (1). The 
structure consists of four domains, an N-terminal -carboxyglutamic acid (Gla) domain that 
contains nine carboxylated glutamic acids, two epidermal growth factor-like regions (EGF-1 
and EGF-2) and a serine protease domain containing the catalytic site residues His57, 
Asp102 and Ser195 (chymotrypsin numbering) (2). Protein C circulates in blood as an 
inactive zymogen that is activated via proteolytic cleavage by thrombin bound to 
thrombomodulin in the presence of the endothelial protein C receptor (EPCR) (3). APC 
down-regulates coagulation by degrading coagulation factors Va and VIIIa, the cofactors for 
factors Xa and IXa, respectively, in enzyme complexes on phospholipid surfaces in the 
presence of factor S (2, 4). In addition to the anticoagulant properties, APC has anti-
inflammatory, anti-apoptotic and cytoprotective effects, which are dependent on the APC-
mediated cleavage of the protease-activated receptor PAR-1 in the presence of EPCR, leading 
to a number of signaling events (1, 3, 5, 6).      
The activity of APC is modulated by Ca
2+. The nine carboxylated glutamates in the 
Gla domain are able to bind to Ca
2+, which changes the conformation of this domain and thus 
allows both the inactive and active forms of protein C to bind to phospholipid membranes. 
Interactions with phospholipids are required for the enzyme complexes catalyzing the 
activation of protein C as well as for those in which APC exerts its proteolytic functions. In 
addition to the Gla domain, APC has one Ca
2+-binding site in the EGF-1 domain and one in 
the 70-80-loop in the serine protease domain (7-9). The binding of Ca
2+ to EGF-1 is required 
for the biological activity of protein C, and it has been proposed that it is involved in the 
interaction of the enzyme with other proteins, including factor S (9). Binding of Ca
2+ to the 
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70-80-loop is accompanied by a conformational change that leads to an 6% decrease in 
tryptophan fluorescence. This interaction is required for the activation of protein C by the 
thrombin-thrombomodulin complex, and it also somewhat stabilizes the amidolytic activity 
of APC (8, 10). A similar enhancement on the amidolytic activity by Mn
2+ ions has been 
observed. This effect is believed to be mediated via the Ca
2+ binding site in the serine 
protease domain of APC (11). The amidolytic activity of APC is also modulated by Na
+ and 
it has been suggested that the 221-225 loop in the serine protease domain forms a binding site 
for this ion (12). A previous report showing that Gla domain-less APC requires Na
+ for its 
amidolytic activity in the absence but not in the presence of Ca
2+, suggested that an allosteric 
link between the Na
+- and Ca
2+-binding loops modulates the structure and function of APC 
(13). 
No metal ions have previously been reported to down-regulate the activity of APC. In 
the present investigation we found that Zn
2+ efficiently inhibits the activity of APC, with both 
a synthetic peptide and factor Va as substrates. We have therefore characterized the 
interaction of Zn
2+ with the enzyme, and its influence on the kinetics of the amidolytic 
reaction. Zn
2+ binding was accompanied by a 40% decrease in tryptophan fluorescence, 
which was used to determine the affinity of APC for Zn
2+. Structural comparisons and other 
data are used to propose reasonable models for how the inhibition might arise. 
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Materials and methods 
 
Proteins  
Human full-length APC and APC lacking the Gla-domain (Des-Gla APC) were purchased 
from Enzyme Research Laboratories (South Bend, IN, USA). The preparations were >90 % 
homogenous in 10 % SDS-PAGE under reducing conditions with the Laemmli system. Both 
the major and minor bands were subjected to peptide mapping by Maldi-Tof MS as described 
before (14), verifying that all bands were APC. The active concentrations of the APC 
preparations, determined by stoichiometric titrations against protein C inhibitor (PCI) with a 
known active concentration (14, 15), were used throughout this study. Human protein S, 
human -thrombin, human factor Xa, human prothrombin and bovine factor V/Va were 
purchased from Enzyme Research Laboratories (South Bend, IN, USA). The active 
concentrations of factor Xa and -thrombin were determined as described previously (14, 
16).  
 
Experimental conditions  
Enzyme assays and fluorescence measurements were conducted at 250.2C and pH 7.4 in 
20 mM Tris-HCl buffer containing 0.1 M NaCl, 0.1 % PEG 8000, except assays containing 
phospholipid vesicles, for which the PEG was excluded. If indicated, various concentrations 
of EDTA or a divalent cation as a chloride or sulfate salt were added. The salts used were PA 
grade from Merck. Unless noted otherwise, all Zn
2+ was added as ZnCl2. The water used in 
buffers had first been purified by the central water purification system at the Uppsala 
Biomedical Center, followed by purification in a Milli-Q instrument (Millipore), and had a 
resistance of 18.2 mega Ohm/cm.   
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Chromogenic assays for APC, thrombin and factor Xa activity  
The amidolytic activity of APC was measured spectrophotometrically in a Hitachi U-2000 
dual-beam spectrophotometer with the chromogenic peptide substrate L-pyroglutamyl-L-
prolyl-L-arginine-p-nitroaniline hydrochloride (S-2366 from Haemochrom Diagnostica, 
Mölndal, Sweden). The increase in absorbance due to product formation was monitored for 
60 seconds at 405 nm. For APC activity, all preincubations were done with at least 100 nM 
APC, a concentration at which the enzyme was stable under the conditions used. The enzyme 
was then diluted to 1-2 nM in buffer containing S-2366 at the start of the measurement. The 
activities of thrombin and factor Xa were measured by similar assays but with the use of the 
chromogenic peptide substrates S-2238 and S-2222, respectively (Haemochrom Diagnostica, 
Mölndal, Sweden), as described before (14, 16). 
 
Kinetics of APC activity in the presence of Zn
2+ 
The effects of Zn
2+ on KM and kcat for the amidolytic activity of APC were determined by 
measuring APC activity by the chromogenic assay in the presence of either 10 M Zn
2+, 100 
M EDTA, 2.5 mM Ca
2+ or 2.5 mM Ca
2+ and 15 M Zn
2+ at S-2366 substrate concentrations 
varying from 0-3 mM. The somewhat higher zinc concentration used in the presence than in 
the absence of Ca
2+ was choosen due to the KD for Zn
2+ being somewhat higher in the 
presence than in the absence of Ca
2+  (see below). Zn
2+ was added to APC at least 2 min 
before each measurement to ensure that equilibrium was reached. The data were analyzed by 
nonlinear regression fitting to the Michaelis-Menten equation to give KM and kcat.   
The apparent inhibition constant, KI, for the inhibition of APC by the ion was 
measured at Zn
2+ concentrations varying from 0-100 M and a constant substrate 
concentration of 0.5 mM. Zn
2+ was added to APC or des-Gla APC at least 2 min before each 
measurement. The determination was done both in the absence and presence of 2.5 mM Ca
2+ 
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for full-length APC and in the absence of Ca
2+ for des-GLA APC. The rate of substrate 
hydrolysis was plotted versus the concentration of Zn
2+. KI was obtained by nonlinear 
regression fitting of this plot to the equation for non-competitive inhibition (Eq. 1) (17). 
vi = KI  v0 /(KI + I)  (Eq. 1) 
where vi is the initial enzymatic rate in the presence of inhibitor, v0 is the initial enzymatic 
rate in the absence of inhibitor and [I] is the concentration of the inhibitor, i.e. Zn
2+.  
 
Inactivation of factor Va by APC 
The effect of Zn
2+ on the activity of APC was also determined with factor Va as a 
substrate. The time course and the Zn
2+ concentration dependence for the inactivation of 
factor Va was measured by a two-stage assay, essentially as described previously (18). In the 
first stage, factor Va (2.4 nM) was incubated with APC (0.2 nM) on 25 µM PC/PS vesicles in 
buffer containing 2.5 mM Ca
2+ in the presence or absence of 100 µM Zn
2+ for 1-12 min. 
Alternatively the time of incubation was fixed at 2 min and the Zn
2+ concentration varied 
from 0 to 100 M, either in the absence or presence of 0.2 nM protein S. In the second stage, 
the remaining factor Va activity was determined in a prothrombinase assay, in which the 
factor Va-enhanced rate of prothrombin activation by factor Xa was determined. The 
incubation mixture from the first stage was diluted 24-fold into the prothrombinase assay, 
which was carried out for 15 min with 25 µM PC/PS vesicles, 0.6 µM prothrombin and 1 nM 
factor Xa at 25°C. The remaining activity of factor Va was determined from the decrease of 
the rate of thrombin generation, as monitored by an amidolytic activity assay with 200 µM S-
2238, with the absorbance measured at 405 nm in an ELISA reader (Infinite M200 from 
Tecan or SpectraMax Plus
384 from MDS Analytical Technologies). All values are the average 
of at least three independent measurements ± standard error.  
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Fluorescence spectra and fluorescence titrations   
Fluorescence spectra and titrations were measured in a volume of 500 l in 0.50.5 cm 
quartz cuvettes with magnetic stirring in an SLM 4800S spectrofluorimeter, modernized with 
Olis electronics and software (Bogart, GA). All fluorescence values reported were corrected 
for dilution and inner filter effects.  
The effect of the interaction of Zn
2+ on the fluorescence of APC was analysed by 
measurements of fluorescence spectra for APC and des-Gla APC. The optimal ex was first 
determined to be 282 nm by excitation spectra. Emission spectra were subsequently measured 
from em 300 to 450 nm at the optimal ex with 2 and 4 nm excitation and emission 
bandwidths, respectively. The spectra were measured at 100-200 nM protein concentrations.  
Equilibrium binding was studied by fluorescence titrations monitored by the decrease 
in tryptophan fluorescence accompanying the interaction of Zn
2+ with APC. Excitation and 
emission wavelengths of 282 and 345 nm, respectively, both experimentally determined to 
give the highest fluorescence, and excitation and emission bandwidths of 2 and 16 nm, 
respectively, were used. APC concentrations varied between 100 and 500 nM. KD values 
were determined by fitting the titration data to the equilibrium binding equation by nonlinear 
least-squares analysis, as described before, assuming a 1:1 binding stoichiometry (15).  
 
Modeling of Zn ion into the catalytic module  
Sequences similar to that of APC were located among the protein entries of GenBank (19) 
and aligned using CLUSTAL W (20). All similar catalytic domain structures were obtained 
from the Protein Data Bank (PDB) (21), then superimposed and compared with the programs 
LSQMAN (22) and O (23). O was used to model the zinc ions and the structural figures were 
prepared using O and Molray (24). 
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Results 
 
Effects of divalent cations on APC amidolytic activity  
The amidolytic activity of APC was measured spectrophotometrically with the use of the 
chromogenic peptide substrate S-2366 (0.5 mM) in the presence of either EDTA or one of the 
metal salts MnCl2, MgCl2, NiCl2, CuSO4, and ZnCl2 (Fig. 1). The effects of all the salts were 
determined at two concentrations, one corresponding to the physiological concentration of 
each metal ion in blood (25-28) and one which was the same for all the salts, i.e. 2.5 mM. 
Three of the salts, NiCl2, CuSO4 and ZnCl2, lowered APC activity in a concentration-
dependent manner. Since Cu
2+, Ni
2+ and Zn
2+ ions have similar sizes (0.7–0.75 Å), the same 
charge and usually similar ligands and coordination, they presumably inhibit APC by similar 
mechanisms. At physiological concentrations Zn
2+ was, however, a more efficient inhibitor 
than Cu
2+ and Ni
2+ and reduced APC activity by 60%. Zn
2+ was chosen for further 
experiments not only because of this efficiency but also because, in contrast to copper ions, it 
is not redox reactive, simplifying the interpretation of the data. It should be noted, however, 
that Cu
2+, besides Zn
2+, also may have a regulatory effect on APC activity. A similar 
inhibiting effect was observed when ZnSO4 was used instead of ZnCl2 (not shown), verifying 
that the metal ion was the inhibiting component in both salts.  
 
Effects of Zn
2+ on APC cleavage of S-2366    
The amidolytic activity of APC was studied at different substrate concentrations in the 
presence of either 100 M EDTA, 10 M ZnCl2 , 2.5 mM Ca
2+ or 2.5 mM Ca
2+ and 15 M 
Zn
2+. The Zn
2+ concentrations used are in the range of the total physiological Zn
2+ 
concentrations in blood. The plots of APC activity versus the substrate concentration fit well 
to the Michaelis-Menten equation (Fig. 2A). The KM value determined in the presence of 
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Zn
2+ was somewhat lower than that determined in the presence of EDTA (Table 1), 
demonstrating that the binding of Zn
2+ does not decrease the affinity of APC for the 
substrate. In contrast, kcat was 7-fold decreased, demonstrating that Zn
2+ dramatically 
inhibits the mechanism by which APC cleaves the substrate. In the presence of 2.5 mM Ca
2+, 
15 M Zn
2+ did not induce any significant effect on KM but reduced kcat 2-fold (Table 1). 
Thus, Zn
2+ inhibited APC by decreasing kcat both in the absence and presence of Ca
2+.   
The amidolytic activities of APC and des-Gla APC were also measured at various 
concentrations of ZnCl2 with 0.5 mM substrate. The plots of the decrease in APC activity 
versus the increase in [Zn
2+] fit well to the equation for non-competitive inhibition (Eq. 1) 
(Fig. 2B) giving KI values of 13  2 and 25  1 M for APC and des-Gla APC, respectively 
in the absence of Ca
2+ (Table 1). These results demonstrate that the Gla-domain is not of 
major importance for the inhibitory effect of Zn
2+ on APC activity. When the amidolytic 
activity was measured in the presence of 2.5 mM Ca
2+, the KI value for zinc inhibition of 
APC was 564 M. At saturating concentration of Zn
2+, the APC activity was completely 
abolished.  
To compare the effect of Zn
2+ on APC activity with that on the activity of 
procoagulant proteases whose cofactors APC degrades, thrombin and factor Xa activities in 
the presence of Zn
2+ were also measured. Only a slight decrease in the activities of these 
proteases was observed in the presence of Zn
2+. The decreases in thrombin and factor Xa 
activities were 40 % at 2.5 mM Zn
2+, corresponding to KI values of over 5 mM. The 
concentrations of Zn
2+ required for the inhibition of thrombin and factor Xa are thus at least 
two orders of magnitude higher than those required for the inhibition of APC.   
The reversibility of the inhibitory effect of Zn
2+ on APC activity was determined by 
adding 20 M EDTA to an APC solution containing 10 M Zn
2+. After the addition of 10 
M Zn
2+, the activity was 59  1 % of the control value and after further addition of EDTA, 
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the activity was fully recovered (103  7 % of the control), where the control was APC 
containing 20 M EDTA. The results thus showed that the inhibitory effect of Zn
2+ on APC 
activity was fully reversible.  
 
Effects of Zn
2+ on the inactivation of factor Va by APC 
The effects of zinc ions on the inactivation of factor Va by APC were determined by a two-
stage assay. In the first stage, factor Va was incubated with APC in the presence of 
phospholipid vesicles and physiological Ca
2+ concentration for various time-points with or 
without 100 M Zn
2+, followed by a prothrombinase assay in the second stage. The zinc 
concentration used was calculated to result in ~83% saturation of the APC (0.2 nM) used in 
this assay, based on the apparent affinity of APC for Zn
2+ in the presence of Ca
2+. The 
activity in the prothrombinase assay as a function of the time of incubation of factor Va and 
APC in the absence or presence of Zn
2+ is shown in Figure 3A. The activity decreased much 
more rapidly in the absence than in the presence of Zn
2+, demonstrating that this ion 
significantly lowered the ability of APC to inactivate factor Va.    
The influence of the Zn
2+ concentration on the inactivation of factor Va was studied 
by a similar two-stage assay as described above but with varying concentrations of Zn
2+ and a 
fixed incubation time of 2 min. This experiment was done in the absence or presence of 
equimolar concentration of the cofactor for APC, protein S. In the absence of factor S, the 
amount of thrombin generated, reflecting the inhibition of APC activity, increased dose-
dependently in a hyperbolic manner from 0-100 M Zn
2+ (Fig. 3B). The inhibitory effect of 
zinc ions was also observed in the presence of the cofactor, although with a shift toward 
somewhat higher Zn
2+ concentrations and a different shape of the Zn
2+-concentration 
dependency. This finding may be partially explained by the previous observation that 
commercial protein S preparations contain very little Zn
2+, in contrast to human protein S 
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purified by immunoaffinity chromatography, which contains the Zn
2+-bound form of the 
protein (29). A small portion of the Zn
2+ used in our assay may thus have been consumed by 
protein S to retain the Zn
2+-bound form of the protein. The concentration of protein S was, 
however, very small compared to that of Zn
2+. Another potential explanation may thus be that 
the Zn
2+-binding site is slightly less exposed when APC is bound to protein S.  
 
Effects of Zn
2+ on tryptophan fluorescence spectra 
The effect of the interaction with Zn
2+ on the fluorescence of APC and des-Gla APC was 
assessed by measurements of tryptophan fluorescence emission spectra for APC and des-Gla 
APC (Fig. 4A  B). The maximal emission was at 345 nm for both proteins. The addition of 
500 M Zn
2+ to 200 nM APC, calculated to give 98% saturation based on the KD 
determined below, resulted in 40 and 30% decreases in the fluorescence intensity at 345 nm, 
for APC and des-Gla APC, respectively. The wavelength of the fluorescence emission 
maximum was not affected by the interaction with Zn
2+. 
The reversibility of Zn
2+-binding to APC was evaluated by measuring tryptophan 
fluorescence emission spectra before and after the addition of 200 M EDTA to 200 nM 
APC containing 100 M ZnCl2 (Fig. 4C). These concentrations of APC and Zn
2+ were 
estimated to result in 93% of saturation of APC. The addition of 200 M EDTA to APC in 
the absence of Zn
2+ resulted in a small decrease in fluorescence, presumably due to EDTA 
quenching the tryptophan fluorescence of APC. The addition of 100 M ZnCl2 to 200 nM 
APC lowered the fluorescence of APC, as estimated, and after further addition of 200 M 
EDTA to this solution, the fluorescence was restored to that of APC containing EDTA but 
not Zn
2+ (Fig. 4C). These findings show that the decrease in fluorescence caused by the 
interaction of Zn
2+ with APC is fully reversible. Similar results were obtained when the 
reversibility of the Zn
2+-induced decrease in fluorescence of des-GLA APC was studied. 
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Emission spectra for APC measured in the presence or absence of Ca
2+ showed a 6% 
decrease in fluorescence at saturating conditions, in agreement with previous reports (8, 30). 
Attempts to restore the 40% Zn
2+-induced decrease in fluorescence by adding excessive 
amounts of Ca
2+ ions were not successful, indicating that Zn
2+ binds to a site distinct from the 
Ca
2+-binding sites on APC. 
 
Binding affinities determined by fluorescence  
The decrease in fluorescence caused by Zn
2+ binding to APC was used to determine apparent 
KD values from fluorescence titration curves. The relatively weak binding affinity precluded 
assessment of binding stoichiometry. The data were well fitted to the equilibrium binding 
equation (15) with the assumption of an equimolar binding stoichiometry (Fig. 5). KD values 
were 7.41.5 and 193 M (Table 1) for the interactions of Zn
2+ with APC and des-Gla APC, 
respectively, in the absence of Ca
2+. In the presence of 2.5 mM Ca
2+ the KD value was 203 
M for the interaction of Zn
2+ with APC.  
 
Discussion 
 
An initial finding in our laboratory that the amidolytic activity of APC was abolished in the 
presence of Zn
2+ initiated this investigation, in which we have characterized the interaction of 
Zn
2+ with APC and quantified the inhibitory effect of Zn
2+ on APC activity. The unaffected 
or somewhat decreased KM and 7-fold decreased kcat, determined by varying the 
concentrations of a chromogenic peptide substrate at a zinc concentration of 10 M, 
demonstrated that Zn
2+ inhibited APC by a non-competitive mechanism. These results 
suggest that metal binds at a position distinct from the active site and that a conformational 
change of APC is involved in generating a catalytically inert form of the protease. Such a 
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conformational change was also supported by the 40% decrease in tryptophan fluorescence 
induced by the binding of Zn
2+ to APC. The agreement  between the KD determined by 
fluorescence and the KI determined by a chromogenic assay, support that Zn
2+-binding results 
in the inhibition of the enzymatic activity. The 3–4-fold higher KD and KI values in the 
presence than in the absence of physiological Ca
2+ concentration showed that Ca
2+ affected 
the affinity of APC for Zn
2+. Nevertheless the inhibition of APC by Zn
2+ was still non-
competitive in the presence of Ca
2+, as demonstrated by the unaffected KM and decreased kcat. 
The catalytic machinery was inhibited by zinc ions both using a chromogenic peptide 
substrate, and in a more physiological assay based on the degradation of factor Va by APC in 
the presence of phospholipid vesicles and physiological Ca
2+ concentration. These results 
thus support a role of zinc ions in regulating the anticoagulant activity of APC.  
The KI in the low micromolar range, comparable to the concentrations of zinc ions 
found in blood plasma and platelets, suggests that the inhibition of APC by these ions may be 
physiologically relevant. The total concentration of zinc ions in blood plasma is 15–20 M, 
whereas the concentration of free zinc is only around 0.15–0.5 M, because the majority of 
these ions in blood are bound to proteins (31-33). Zinc ions are, however, enriched in 
platelets at a total concentration of approximately 500 M, distributed between the -
granules and cytoplasm (33). Several previous studies have shown that zinc ions are released 
during platelet activation and it has been proposed that such release leads to a local increase 
in the concentration of Zn
2+ at the platelet surface (34-37). The exact concentration of Zn
2+ at 
this surface is difficult to estimate. Blood coagulation is, however, known to be very local 
and restrictive. Since the surface of the activated platelet is a potential site of action of APC, 
due to the presence of factors Va and VIIIa of the tenase and prothrombinase complexes, 
respectively, it is highly possible that the activity of APC is down-regulated by Zn
2+ on this 
surface. The Zn
2+-concentration dependence for the inactivation of factor Va by APC 
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determined in this study was clearly dose-dependent in a hyperbolic manner from 0-100 M 
Zn
2+, but was somewhat shifted to higher Zn
2+ concentration in the presence of factor S. This 
latter finding may relate to the need for protection against Zn
2+ inhibition in situations where  
anticoagulation is needed. The more than two orders of magnitude higher KI values for the 
inhibition of factor Xa and thrombin by Zn
2+ than for the inhibition of APC supports the 
conclusion that Zn
2+ may regulate APC activity. In further support of this conclusion, it has 
been shown that APC inactivates factor Va much more efficiently on artificial phospholipid 
membranes or endothelial cells than on platelets (38). Cu
2+ ions, which are also found in 
platelets, may contribute to such effect (39). 
The inhibitory effect of Zn
2+ on APC activity described here is in line with the overall 
procoagulant effect of Zn
2+, which has recently been reviewed (31). Deficiency of Zn
2+ in the 
diet results in a decrease in the concentration of Zn
2+ in blood and, as a consequence, leads to 
a tendency for clotting disturbances (40). For instance, the ion induces platelet aggregation 
and fibrin clot formation (40, 41). Moreover, Zn
2+ has been proposed to lower the 
anticoagulant action of antithrombin, by enhancing the binding affinity of histidine-rich 
glycoprotein for heparin and thus neutralizing the anticoagulant activity of heparin in plasma 
(37). Apart from blood, protein C is expressed in several other tissues 
(http://www.proteinatlas.org). Another potential physiological role for Zn
2+ inhibition of 
APC may thus be to prevent unwanted proteolytic activities in such tissues where the 
concentrations of zinc ions are high, including the reproductive system and various parts of 
the central nervous system, such as the hippocampus (32).   
Interestingly, two of the proteins that APC interacts with have already been identified 
as Zn
2+ binders. It was recently discovered that plasma protein S contains Zn
2+ and that this 
ion is essential for the APC-independent anticoagulant activity of protein S (29). The finding 
that the Zn
2+-content in protein S preparations does not influence the APC-dependent 
Page 15 of 36 Thrombosis and Haemostasis
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60For Peer Review
  16 
anticoagulant activity of protein S (29) is in line with our observation that the inhibitory 
effect of Zn
2+ on APC anticoagulant activity is caused by the ion binding to APC. Earlier it 
was shown that 2-macroglobulin is a Zn
2+-binding protein in blood (32). Additionally, other 
serine proteases involved in the regulation of blood coagulation are affected by Zn
2+, 
including factor XII, factor XI and factor VIIa
 (31). For factor VIIa, the catalytic machinery 
is inhibited by Zn
2+ ions, as for APC. Two Zn
2+ sites have been proposed in factor VIIa that 
are distal from the catalytic site but overlap the Ca
2+ binding site (42). The functional 
consequence of the inhibitory effects of zinc ions on factor VIIa activity are, however, 
opposite to those on APC activity, since factor VIIa functions as a procoagulant in the 
presence of tissue factor. For APC, a procoagulant effect exerted by Zn
2+ seems 
straightforward to explain from a functional point of view, assuming that such inhibition 
occurs at sites of injury where platelets accumulate and coagulation is required to prevent the 
loss of blood.  In contrast, the anticoagulant effects induced by the interaction of Zn
2+ with 
protein S and factor VIIa would make sense only if they occur at sites where coagulation is 
not wanted, such as the healthy endothelium.  Future investigations are required to clarify the 
physiological functions of all these Zn
2+-protein interactions  
The inhibitory effect of Zn
2+ on APC activity may be contrasted with the activation of 
the enzyme by Ca
2+ (7, 8, 10), which raised the question of whether Zn
2+ merely displaces 
Ca
2+ from its binding site, as for factor VIIa. This possibility could, however, be excluded for 
several reasons. We have shown that the interaction of Zn
2+ with APC is reversible, along 
with the fluorescence change induced by the interaction of Zn
2+ with APC. The decrease in 
fluorescence induced by Ca
2+-binding to APC is only 6% whereas the decrease in 
fluorescence induced by Zn
2+ binding is 40%. Thus, if Zn
2+ was binding to the Ca
2+-binding 
site, an increase in fluorescence should be observed when excessive amounts of Ca
2+ are 
added to Zn
2+-bound APC. This does not happen. Moreover, the greater effect on the intrinsic 
Page 16 of 36 Thrombosis and Haemostasis
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60For Peer Review
  17 
fluorescence of APC induced by Zn
2+ than by Ca
2+ (8, 30) indicates that the two metal ions 
induce different conformational changes in APC. Finally, Zn
2+ was able to completely 
abolish the amidolytic activity of APC, whereas Ca
2+ somewhat stabilizes but is not required 
for the amidolytic activity of the enzyme (8). Since the KI and KD values observed for the 
interaction of Zn
2+ with APC were 3-4-fold higher in the presence than in the absence of 
Ca
2+, it thus appears as if the Zn
2+-binding site is affected by the conformational change 
induced by Ca
2+. The similar influence of Zn
2+ on des-Gla APC and full-length APC 
demonstrated that the Zn
2+-binding site is not located in the Gla domain, which contains 
several Ca
2+-binding sites. Together, these findings suggest that Zn
2+ binds to a site that is 
distinct from the Ca
2+ binding site in the 70-80 loop, but located, at least partially, in the 
serine protease domain.  
To identify potential Zn
2+-binding sites, we sought appropriate residues (histidine, 
cysteine, aspartate and glutamate, accounting for 97% of amino acids in Zn
2+ sites) (43) that 
are clustered in the structure of human APC or could be envisioned to be close after 
conformational changes. A careful consideration of PDB entry 1AUT (44) indicated several 
potential sites. The simplest possibility is illustrated in Fig. 6A  B. The structure of an 
engineered trypsin mutant with a 21 µM KD for Cu
2+ has been reported elsewhere (45), 
showing that the equivalent of His57 can assume a different conformation, allowing it to 
form part of an ion binding site. A similar motion of the charge-relay histidine was reported 
still earlier for Zn
2+ binding in the tonin structure (46). In APC, possible zinc binding 
residues close to His57 include Asp60 and Glu60A. Since this histidine is an essential 
component of the catalytic triad, a change in conformation would render the enzyme inactive; 
this could easily occur without disrupting substrate binding, and so KM. However, the large 
change in tryptophan fluorescence of APC on Zn
2+ binding suggests that additional, more 
extensive conformational changes also occur. Looking for conserved residues in APC, we 
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found two clusters that are also candidates for ion-binding sites. One of these includes His48, 
Ser50, His107 and Trp51, as modeled in Fig. 6C. It is not clear whether the interaction of 
Zn
2+ with these residues would affect the catalytic machinery. His91, His241 and Trp237 
comprise another cluster, but since the latter residues are also present in other blood clotting 
proteases, they are not likely to give an effect specific for APC. These sites, however, include 
residues less commonly involved in Zn
2+ binding. A potential Zn
2+ site includes residues in 
the 144-153 loop, i.e. His144/Glu148/Glu149A, and possibly Asp18. The loop is an insertion 
in APC relative to other sequences, but the proposed Zn
2+-binding residues are not as 
strongly conserved in mammalian APC sequences as one would expect if the function is 
widespread. In this model, an extensive conformational change would be required to convey 
the information to the active site. Clearly, a number of structural, mutational and other studies 
will be required to understand the basis of zinc binding and inhibition. 
The ability of Zn
2+ to inhibit the amidolytic activity of APC is a highly interesting 
finding that broadens our understanding of the physiological function of this versatile serine 
protease, which is capable of inhibiting blood coagulation as well as inflammation and 
apoptosis. Furthermore, it is medically interesting from several points of view. APC is used 
clinically to treat patients with severe sepsis (47) and has the potential to be used in future 
treatments of several additional thrombotic and/or inflammatory diseases, including stroke 
(48), multiple sclerosis (49) and diabetic endothelial and glomerular injury (50). Knowledge 
about the Zn
2+-binding site may therefore be used to produce specialized recombinant forms 
of APC that are resistant to inhibition by Zn
2+. Such engineering could be combined with 
other tailor-made structural features of the enzyme to give a potentially improved therapeutic 
effect. 
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Figure legends 
 
Figure 1. Effects of metal ions on the amidolytic activity of APC. APC activity was 
measured spectrophotometrically with the use of the chromogenic peptide substrate, S-2366, 
as described in Materials and methods. The activity of APC measured in 100 M EDTA in 
the absence of metal ion was used as a control and was set to 100% activity. The values are 
the means  SE of two measurements. 
 
Figure 2.  Amidolytic activity of APC and des-GLA APC measured 
spectrophotometrically with the substrate S-2366. (A) The influence of substrate 
concentration on the rate of substrate hydrolysis by APC was determined in the presence of 
100 M EDTA (), 10 M Zn
2+ (), 2.5 mM Ca
2+ () or 15 M Zn
2+ and 2.5 mM 
Ca
2+(). Solid lines represent nonlinear regression fitting to the Michaelis-Menten equation. 
(B) The influence of the concentration of Zn
2+ at 0.5 mM S-2366 on the amidolytic activity 
of APC in the absence () and presence () of 2.5 mM Ca
2+ and of des-Gla APC in the 
absence of 2.5 mM Ca
2+ () is shown. Solid lines represent nonlinear regression fitting to the 
equation for non-competitive inhibition to give the inhibitor constant, KI (Eq. 1) (17). 
 
Figure 3. Influence of zinc ions on the inactivation of factor Va by APC  
(A) Factor Va was incubated with APC in the presence of phospholipid vesicles and Ca
2+ for 
various time points in the absence () or presence () of 100 M Zn
2+, followed by the 
determination of the remaining activity in a prothrombinase assay, as described in Materials 
and methods. All values are the means  SE of at least three measurements. The amount of 
thrombin generated in the absence of APC was set to 100%. The solid lines represent 
nonlinear regression fitting to a biphasic exponential function. (B) Factor Va was incubated 
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with APC in the absence () or presence () of protein S. The assay, containing 
phospholipid vesicles and Ca
2+, was run for 2 min at various Zn
2+ concentrations, followed 
by the determination of the remaining activity in a prothrombinase assay, as described in 
Materials and methods. For each curve, the increase in the activity of thrombin generated is 
expressed as % increase related to that generated in the absence of Zn
2+. The solid line for 
data collected in the absence of protein S represents nonlinear regression fitting to a 
hyperbolic binding equation. The values are the means  SE of three measurements.  
 
Figure 4. Zn
2+-induced changes in tryptophan fluorescence and effects of EDTA. 
Uncorrected emission spectra determined at 25 C as described in Materials and methods. (A) 
The effect of 500 M Zn
2+ on the fluorescence of 200 nM APC and (B) 200 nM des-GLA 
APC. (C) Effects of adding 200 M EDTA to 200 nM APC in the absence or presence of 100 
M Zn
2+. Solid black lines, emission spectra of APC or des-Gla APC in the absence of Zn
2+ 
and EDTA; Dotted lines, emission spectra of Zn
2+-bound APC or des-Gla APC; Dashed 
lines, emission spectra of APC containing EDTA; Solid gray lines, emission spectra of 
EDTA added to Zn
2+-bound APC;  
 
Figure 5. Equilibrium binding, studied by tryptophan fluorescence titrations, for the 
interaction of Zn
2+ with APC and des-Gla APC. Typical fluorescence titrations are shown 
for the interactions of Zn
2+ with APC in the absence () and presence () of 2.5 mM Ca
2+ 
and des-Gla APC in the absence of Ca
2+ (). The concentrations used of APC and des-GLA 
APC were 200 nM. Solid lines represent nonlinear regression fitting to the equilibrium 
binding equation (15), assuming a 1:1 binding stoichiometry. 
 
Figure 6. Models of Zn
2+ binding to human APC. 
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(A) Stereo representations of human APC (PDB entry 1AUT) and anionic trypsin mutant 
Arg96His (PDB entry 1AND) are shown in red and aquamarine, respectively. The Cu
2+ ion 
in trypsin is shown as a dark green sphere. (B) Model of the binding of Zn
2+ (magenta 
sphere) into the APC active site with only small conformational changes. (C) Model of Zn
2+ 
(yellow sphere) binding to a conserved APC site.    
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Table 1. Influence of Zn
2+ on the inhibition constant, turnover number and Michaelis 
constant for the amidolytic activity of APC and affinity of APC for Zn
2+. The amidolytic 
activity of APC was measured spectrophotometrically with the use of the substrate S-2366, as 
described in Materials and methods. The data from determinations at different substrate 
concentrations in the presence of either 100 M EDTA, 10 M Zn
2+, 2.5 mM Ca
2+ or 15 M 
Zn
2+ and 2.5 mM Ca
2+ were fit to the Michaelis-Menten equation (Fig. 2A) to give the 
Michaelis constant, KM, and turnover number, kcat. The values  SE were obtained by 
nonlinear regression fitting. Inhibitor constants, KI, are the means  SE of 3-4 plots of the 
amidolytic activity of APC and des-Gla APC versus [Zn
2+], determined in the absence or 
presence of 2.5 mM Ca
2+ (Fig. 2B). Equilibrium dissociation constants, KD, for the 
interaction of Zn
2+ with APC are the means  SE from 3-4 tryptophan fluorescence titrations 
(Fig. 5).  
APC form  Additions  KM (M)  kcat (s
-1)  KI (M) K D (M) 
APC   EDTA  27030  201  –  – 
APC  Zn
2+  14050  2.70.2  131  7.41.5 
APC  Ca
2+  35070  181  –  – 
APC    Ca
2+ + Zn
2+  36080  101  574  203 
Des-Gla APC  Zn
2+  nd
a  nd
a  253  193 
a nd; not determined 
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What is known about this topic? 
 
  It is known that activated protein C (APC) has several binding sites for Ca
2+, 
one in the serine protease domain, one in the EGF-1 domain and nine in the 
GLA domain. Additionally, APC has one Na
+-binding site in the serine 
protease domain.  
  It is known that binding of Ca
2+ to the serine protease domain is required for 
the activation of protein C by the thrombin-thrombomodulin complex.  
  The binding of Ca
2+ and Na
+ to the serine protease domain allosterically 
regulate APC, resulting in enhanced enzymatic activity.  
 
What does this paper add? 
 
  This article shows that Zn
2+ reversibly inhibits APC by a non-competitive 
mechanism. Inhibition occurs both with a chromogenic peptide and factor Va 
as substrates.  
  This article further shows that the interaction of Zn
2+ with APC is 
accompanied by a ~40 % decrease in tryptophan fluorescence. Apparent KD 
and KI values in the low micromolar range suggest that the inhibition may be 
relevant for the anticoagulant functions of APC. 
  Finally, this article presents several amino acid clusters that are potential sites 
for Zn
2+ binding.  
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